
About 7 out of 10 Alzheimer’s patients wound up free of the brain plaques that are a hallmark of the disease after treatment with a potentially breakthrough experimental drug, clinical trial results show. The drug, donanemab, also significantly slowed the patients’ brain decline, according to findings published March 13 in the New England Journal of… read on > read on >